THE SHARE:
Change: -0.01 SEK (-4.53%) / Price: 0.13 SEK / Feb 11, 2026, 5:29 pm (CET)
Home
About
Introduction
Board of Directors
Management Team
Medical Advisors
Corporate Governance
Career
Technology
Physiological Targeting
Functional Nanoparticles
Publications
Patent
Portfolio
Pipeline
SpagoPix
Tumorad
Investor Relations
The Share
Analyst Coverage
Owners
Financial Reports
Financial Calendar
Equity research
Shareholder’s Personal Data
Share Issue
Media
Spago Nanomedical in media
Press Releases
Subscribe
Presentations
Events
Image Bank
Contact
Contact us
mfn-ext-nq
3 Jun, 2025
Spago Nanomedical continues patient recruitment in the phase I/IIa study Tumorad-01 as planned after DMC recommendation
3 Jun, 2025
Spago Nanomedical fortsätter planenligt patientrekryteringen i fas I/IIa-studien Tumorad-01 efter DMC-rekommendation
1
2
Previous
Back